Ascentage Pharma Group Inc.
Clinical trials sponsored by Ascentage Pharma Group Inc., explained in plain language.
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a new drug called APG-1252 combined with the standard pill osimertinib in 80 people with EGFR-positive non-small cell lung cancer that has stopped responding to other targeted therapies. The goal is to find a safe dose and see if the combination can s…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC